Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a reminder that my colleague Ed Silverman is hosting a discussion today about the long-awaited arrival of Humira biosimilars and all they portend for drug costs, insurance coverage, and pharma revenues. Sign up to tune in here.
The need-to-know this morning
- AstraZeneca said it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.
- The U.K.’s cost-effectiveness watchdog said it is not yet recommending Vertex Pharmaceutical’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.
Small studies offer hope for treating brain cancer
Data from a handful of patients with a deadly, incurable form of brain cancer suggest cell therapy could become a powerful treatment.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect